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Background
HER2 is a commonly expressed tumor-associated antigen
in breast (BrCa) and, therefore, an attractive target for
immunotherapy. We have investigated HER2-derived
peptides as vaccines mixed with GM-CSF to include GP2
(a HLA-A2 and HLA-A3 restricted, CD8+ eliciting epi-
tope) and AE37 (a HLA unrestricted, MHC class II, CD4
+ eliciting epitope). Both peptide vaccines (PV) have
shown clinical promise individually and there is clear
rationale for combining GP2 and AE37 to elicit a more
robust immune response (IR) of both CD4+ and CD8+
T cells. Here, we report the results of in vitro, CD8+,
T-cell proliferation in response to the AE37 epitope.
Methods
After completion of standard therapy, disease-free, node
positive or high-risk, node negative BrCa or ovarian cancer
patients received AE37/GP2+GM-CSF in six monthly
intradermal inoculations (R1-R6). To determine HER2-
induced proliferation, a 3H-thymidine incorporation assay
was used. Specifically, peripheral mononuclear blood cells
(PMBC) were isolated from blood samples taken at base-
line, R3, R6, six months after the primary vaccine series
(RC6), and 12 months post-PVS (RC12). PMBC were then
exposed to the AE37 peptide or culture media (CM) as a
control. After incubation with radioactive-thymidine and
cell lysis, a scintillation counter was used to measure the
amount of thymidine incorporation into DNA in counts
per minute (cpm). Data are expressed as means +/-SEM
and compared using student’s t-test.
Results
Of the 28 vaccinated patients, PMBC from 22 patients
were available. Data units are measured in cpm. Results
are presented in the table below (Table 1).
Conclusions
During the primary vaccination series, an AE37/GP2+GM-
CSF dual peptide vaccine results in robust T-cell prolifera-
tion. However, significant immune responses become
more variable at six and twelve months post vaccination
suggesting the need for boosters in some individuals.
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p-value 0.57 0.02 0.06 0.11 0.35
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